Indeed, anti-VEGF therapy has been shown to normalize vessels and allow T-cell penetration in HCC [1], so a tumor’s attempt to hide via vasculature can be countered by continuing bevacizumab in combination with immune activation. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.